Avadel Pharmaceuticals Plc's (AVDL) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 
Avadel Pharmaceuticals Plc  (NASDAQ: AVDL)
 



  Avadel Pharmaceuticals Plc Outlook

On January 8 2025 the Avadel Pharmaceuticals Plc provided following guidance

Avadel Pharmaceuticals Plc. has recently disclosed their financial projections, offering insights into their expected performance for the fourth quarter of 2024 and their strategic focus for 2025, particularly in relation to the launch of LUMRYZ.

The company anticipates generating around $50.0 million in net revenue from LUMRYZ sales for the final quarter of 2024. This estimate reflects a remarkable increase of over 150% compared to the $19.5 million reported for the same quarter in 2023. This significant growth indicates a robust market demand and effective commercialization strategies as Avadel pivots towards expanding the reach of LUMRYZ.

Furthermore, Avadel projects that by the close of 2024, there will be approximately 2,500 patients actively using LUMRYZ. This includes an anticipated 600 new patients who are expected to start their treatment during the last quarter of the year. The company's efforts to broaden patient access and enhance healthcare provider awareness will be critical to achieving these targets.

In summary, Avadel Pharmaceuticals is strategically positioning itself to ensure a successful launch of LUMRYZ, with ambitious goals set for revenue growth and patient enrollment that highlight the product's potential in the market.,





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.